JMS Co., Ltd. (7702) AI Stock Analysis

• Market Cap: ¥10.95B
• Dividend Yield: 3.73%
• Average Volume (3M): 30.96K
• Price to Earnings (P/E): 124.7
• Beta (1Y): 0.63
• Revenue Growth: 3.36%
• EPS Growth: -310.49%
• Country: JP
• Employees: 5,283
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -18.76
• Shares Outstanding: 24,733,465
• 10 Day Avg. Volume: 20,020
• 30 Day Avg. Volume: 30,963
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥464.00
• Price Target Upside: 1.75% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 60 Neutral
• Price Target: ¥464.00 ▲(1.75% Upside)

The overall score is driven by stable financial performance with revenue growth and a solid balance sheet, but profitability issues and negative free cash flow are concerns. Technical indicators show positive momentum, while valuation metrics highlight challenges with a negative P/E ratio, offset by a high dividend yield.

JMS Co., Ltd. Business Overview & Revenue Model

Company Description

JMS Co.,Ltd. manufactures, sells, exports, and imports medical devices and pharmaceuticals in Japan and internationally. The company offers infusion and transfusion sets, infusion sets with a needleless access port, disposable needles and syringes, safety scalp vein sets, safety venous indwelling catheters, extension tubes, oral/enteral nutrition systems, infusion and syringe pumps, semisolid nutrition feeding devices, blood bags, blood collection scale and mixers, high-frequency tube sealers, and serum collection sets for infusion and transfusion therapy. It also provides general medical supplies, including latex surgeon's gloves and examination gloves, plastic gloves, treatment sheets, surgical gowns, masks and caps, drainage bags, and surgical tapes used in medical institutions. In addition, the company offers central dialysate delivery systems, hemodialysis machines, AV fistula needles, accidental needlestick prevention systems, hemodialysis blood tubing sets, dialyzers, prefilled syringes, hemodialysis kits, single patient dialysis machines, dialysis solution for CAPD, and automatic peritoneal dialysis machines for hemodialysis and peritoneal dialysis. Further, it provides cardiovascular therapy products, such as cardiopulmonary equipment, membrane oxygenators, heat exchangers, pacemakers, microcatheters, and cardiopulmonary blood tubing sets. JMS Co.,Ltd. was incorporated in 1947 and is headquartered in Hiroshima, Japan.

How the Company Makes Money

JMS Co., Ltd. generates revenue primarily through the sale of its medical devices and healthcare equipment to hospitals, clinics, and other medical institutions. The company's key revenue streams include the production and distribution of infusion pumps, which are essential for administering fluids and medications, and blood purification systems used in dialysis treatments. JMS Co., Ltd. also benefits from strategic partnerships and collaborations with healthcare providers and research institutions, which enhance its product offerings and expand its market reach. Additionally, the company invests in research and development to innovate and improve its product line, thereby maintaining a competitive edge in the medical device industry.

JMS Co., Ltd. Financial Statement Overview

Summary

JMS Co., Ltd. shows revenue growth and improved gross profit margins, but profitability is weak with a low net profit margin and declining ROE. The balance sheet is stable with moderate leverage, but negative free cash flow indicates challenges in capital expenditure management.

Income Statement

JMS Co., Ltd. has shown steady revenue growth with a 6.8% increase from 2024 to 2025. The gross profit margin improved to 22.8% in 2025 from 21.6% in 2024. However, net profit margin remains weak at 0.13% for 2025, indicating challenges in cost management or pricing strategy. EBITDA margin slightly improved to 6.9%, suggesting operational improvements but net income volatility impacts profitability.

Balance Sheet

The company maintains a solid equity base with an equity ratio of 50.2% in 2025, reflecting a stable financial structure. The debt-to-equity ratio is moderate at 0.60, indicating manageable leverage. However, return on equity dropped from 2.2% in 2023 to 0.22% in 2025, highlighting reduced profitability on shareholders’ investments.

Cash Flow

Cash flow analysis reveals challenges with negative free cash flow in 2025 at -1.42 billion JPY, down from a positive 498 million JPY in 2024. Operating cash flow to net income ratio is robust at 16.6, suggesting strong cash generation relative to net income, but the negative free cash flow signals a need for better capital expenditure management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	69.75B	69.75B	65.29B	63.74B	58.17B	57.58B
Gross Profit	15.93B	15.93B	14.09B	14.60B	14.27B	15.10B
EBITDA	4.43B	4.79B	4.08B	4.38B	4.59B	5.64B
Net Income	90.00M	89.00M	-36.00M	281.00M	826.00M	1.74B
Balance Sheet
Total Assets	81.43B	81.43B	84.71B	74.41B	71.97B	69.08B
Cash, Cash Equivalents and Short-Term Investments	5.51B	5.51B	10.31B	6.33B	6.81B	6.22B
Total Debt	24.55B	24.55B	26.92B	19.75B	18.71B	18.50B
Total Liabilities	40.50B	40.50B	43.96B	35.71B	34.88B	34.09B
Stockholders Equity	40.84B	40.84B	40.57B	38.53B	36.96B	34.84B
Cash Flow
Free Cash Flow	0.00	-1.42B	498.00M	-1.07B	1.14B	481.00M
Operating Cash Flow	0.00	1.48B	3.14B	2.48B	4.40B	3.74B
Investing Cash Flow	0.00	-3.14B	-4.24B	-3.69B	-3.68B	-3.25B
Financing Cash Flow	0.00	-3.19B	4.78B	525.00M	-499.00M	-535.00M

JMS Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 456.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Positive. The current price of 456 is above the 20-day moving average (MA) of 449.40, above the 50-day MA of 440.52, and above the 200-day MA of 440.18, indicating a bullish trend. The MACD of 3.46 indicates Positive momentum. The RSI at 61.66 is Neutral, neither overbought nor oversold. The STOCH value of 51.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7702.

JMS Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7702	60 Neutral	¥10.95B	124.68		3.73%	3.36%	-310.49%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
HGYMF	―	$504.82M	91.01	1.63%	1.99%	―	―
7730	75 Outperform	¥123.59B	22.60		3.15%	5.82%	-20.09%
7980	73 Outperform	¥5.76B	8.65		1.84%	5.45%	0.23%
7743	67 Neutral	¥16.62B	14.91		2.72%	2.38%	-48.68%
7979	67 Neutral	¥70.05B	17.22		2.53%	6.82%	-1.08%

JMS Co., Ltd. Corporate Events

JMS Co., Ltd. Faces Financial Challenges Amid Declining Sales

JMS Co., Ltd. reported a decrease in net sales and operating profit for the first quarter of the fiscal year ending March 2026. The company’s net sales fell by 3.9% compared to the previous year, while it recorded an operating loss of 176 million yen. The comprehensive income also showed a significant decline, and the capital adequacy ratio slightly decreased, indicating financial challenges. Despite these setbacks, the company maintained its dividend forecast, suggesting a commitment to returning value to shareholders.